Message from
our Management team.
At Neurocentrx, we are committed to transforming mental health care by making safe, effective, and scalable treatments available to those who need them most. Our lead program, NRCx-201—a patented, abuse-deterrent oral ketamine capsule—represents a novel approach to treating mood disorders, offering a pathway from clinic-based administration to supervised home care through digital safety integration.
With our Phase 1 data published in a peer-reviewed journal, a Phase 2 trial funded by the Wellcome Trust underway in treatment-resistant bipolar depression, and a growing network of scientific and clinical collaborators, we are entering a pivotal stage of growth. These milestones reflect both the urgent need and strong market opportunity for innovative CNS therapies that prioritize patient access without compromising safety.
As we build toward regulatory engagement and broader clinical validation, we remain focused on delivering long-term value—through meaningful innovation, rigorous science, and scalable care models that aim to redefine the standard of treatment for depression and bipolar disorder.
Thank you for your continued interest and support.
Key Figures.
£10m investment since 2014
Successful Phase 1 trial
Multiple indications & scalable safety platform
Multiple dose levels
2 patents
25+ years sector experience within the senior team
King’s College
“Working with Neurocentrx has been a most rewarding experience.
“They bring a combination of enthusiasm, professionalism, scientific rigour and sound business sense to projects.
“I really look forward to working with them in the future.”
Professor Allan Young,
Head of School, Academic Psychiatry.
Director, Centre for Affective Disorders,
Institute of Psychiatry, Psychology and Neuroscience (IoPPN)
King’s College London.
Caritas Science Solutions
“It has been a privilege working with the lovely team at Neurocentrx from the start of their journey into clinic, and a joy to have grown and shared successes together over the last couple of years.
“We are proud to support a company which shares our vision and passion to make a difference in mental health, and we look forward to seeing the immense impact they will have in years to come.”
Leigh Fell,
Chief Executive Officer,
Caritas Science Solutions.
DataMagik
“Neurocentrx’s clear communication throughout the trial has been invaluable in making the set-up and running of the trial go smoothly. The team is friendly, personable and respond to any queries in a timely manner.”
DataMagik.
Rapport
“Rapport has been working with the Neurocentrx team as its regulatory partner for six months now.
“They have been very clear regarding their ambitions and accepting of advice and support where needed. We have moved forward very quickly and professionally so that Neurocentrx have the direction they need.”
Lorna Griffin,
Chief Executive Officer,
Rapport.